StockNews.com Upgrades Atossa Therapeutics (NASDAQ:ATOS) to Hold

StockNews.com upgraded shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) from a sell rating to a hold rating in a research note published on Tuesday. A number of other research analysts have also recently commented on ATOS. HC Wainwright boosted their target price on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the […]

Related Keywords

Jonathan Finn ,Securities Exchange Commission ,Vanguard Group Inc ,Nasdaq ,Atossa Therapeutics Inc ,Connor Clark Lunn Investment Management Ltd ,Cantor Fitzgerald ,Atossa Therapeutics Company Profile ,Atossa Therapeutics ,Free Report ,Get Free Report ,Director Jonathan Finn ,Exchange Commission ,Lunn Investment Management ,Vanguard Group ,Atossa Therapeutics Daily ,